US court rejects Natco Pharma partner’s complaint over Ibrutinib tablets | Tech Reddy

[ad_1]


MT Newswires 2022

All news about NATCO PHARMA LIMITED

Sale 2023 29 037 M
359 M
359 M
Net income 2023 8 527 M
105 M
105 M
Net debt 2023

P/E ratio 2023 12.5x
Harvest 2023 1.27%
Capitalization 106 B
1 309 M
1 309 M
Cap. / Sale 2023 3.65x
Cap. / Sale 2024 2.96x
Number of employees 4 025
Free-Float 48.6%

Chart NATCO PHARMA LIMITED


Duration:

Period:




NATCO Pharma Limited Technical Analysis Chart |  MarketScreener

Technical Analysis Trends NATCO PHARMA LIMITED

Short term Medium term A long time
Trends Bearish Bearish Bearish

Evolution of the Income Statement

Sat

Buy in

Average consensus PRIVILEGE
Number of analysts 12
Final closing price 580.45 INR
Average target price 715.33 INR
Spread / Average Target 23.2%


[ad_2]

Source link